Opendata, web and dolomites

Oncosmart

ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Oncosmart" data sheet

The following table provides information about the project.

Coordinator
CELLPLY SRL 

Organization address
address: VIA FONDAZZA 53
city: BOLOGNA
postcode: 40125
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://cellply.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLPLY SRL IT (BOLOGNA) coordinator 50˙000.00

Map

 Project objective

The advent of personalized cancer care demands for distributed diagnostic solutions to support clinical decisions and selection of the best therapeutic regimen. Supportive information can be obtained by analyzing the response of patient’s tissue to various treatment options. A specific opportunity arises in the field of cellular analysis, where the ex-vivo assessment of drug efficacy performed through drug response assays represents a powerful tool and, at the same time, a challenge due to the difficulty of maintaining in-vitro conditions that closely resemble in-vivo cell response.

CellPly developed a novel in-vitro diagnostic (IVD) product to define cell response to anti-cancer drug treatment through integrated drug response analyses. Oncosmart platform includes a smart consumable, integrating a hybrid polymer/flexible-PCB micro-technology, an analytical instrument and diagnostic software.

After patient’s tissue sampling, an automated process will carry out sample preparation, precise drug delivery and monitoring of cell response through time-lapse imaging. Cancer patients will benefit from more personalized cancer therapies, while the public health systems will reduce overall analysis and hospitalization costs and better allocate resources dedicated to cancer therapies.

The Phase 1 project will set up the a quality-certified manufacturing chain and plan the validation of the platform in clinical setting in the field of acute leukemia; regulatory pathways to comply with CE-IVD and to seek reimbursement will be assessed; the commercialization strategy and associated business model(s) will be elaborated.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOSMART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOSMART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More